SRR934835
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 14.19185282522996
- age_years
- 57
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.584
- UNFOLDED_PROTEIN_RESPONSE+0.581
- G2M_CHECKPOINT+0.579
- ANGIOGENESIS+0.574
- MTORC1_SIGNALING+0.557
- MYC_TARGETS_V1+0.547
- HYPOXIA+0.535
- E2F_TARGETS+0.533
- IL6_JAK_STAT3_SIGNALING+0.528
- MYC_TARGETS_V2+0.527
Top 10 suppressed
- KRAS_SIGNALING_DN-0.401
- PANCREAS_BETA_CELLS-0.297
- BILE_ACID_METABOLISM-0.274
- MYOGENESIS-0.140
- SPERMATOGENESIS-0.116
- XENOBIOTIC_METABOLISM-0.085
- FATTY_ACID_METABOLISM-0.023
- PEROXISOME-0.006
- ESTROGEN_RESPONSE_LATE+0.002
- APICAL_SURFACE+0.035
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C9EE359E-2F42-4D20-880D-FBF8B4953731 | — | — | 0.969 |
| 2 | D5191F3D-028E-401C-927E-483F6884BE39 | — | — | 0.969 |
| 3 | SRR934965 | — | — | 0.967 |
| 4 | SRR934837 | — | — | 0.962 |
| 5 | 1B940F72-3C90-43C4-9267-185F21D10AC9 | — | — | 0.961 |
| 6 | 2B311620-94F3-4B53-B66A-81AC0A32453B | — | — | 0.956 |
| 7 | SRR934730 | — | — | 0.955 |
| 8 | SRR934926 | — | — | 0.954 |
| 9 | 65F93AB7-AA99-49B5-8D59-7D0DE9CA9E34 | — | — | 0.952 |
| 10 | SRR934958 | — | — | 0.951 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.584 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.581 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.579 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.574 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.557 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.547 | Inavolisib | — uncovered |
| HYPOXIA | 0.535 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.533 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.528 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.527 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.432 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.431 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.424 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.420 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.389 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.386 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.375 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.367 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.358 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.347 | Inavolisib | — uncovered |